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Abstract 
Metabolic Syndrome (MS) can be diagnosed from the age of 
10 years, when the coexistence of abdominal obesity, glucose 
metabolism disorders, dyslipidemia, and hypertension is 
observed. A binding part of MS is insulin resistance. Severe 
insulin resistance may be caused by a mutation in lamin 
(LMNA) gene. A teenager with MS due to mutation in 
LMNA gene is presented. 
A 17.5-yr-old Caucasian girl was admitted to the hospital 
with the suspicion of diabetes mellitus due to causal blood 
glucose 393 mg/dl (21.8 mmol/l), without typical diabetic 
symptoms. Since the age of 13 years she had been presented 
with excessive weight gain, hirsutism, and oligomenorrhoea. 
Her family history was positive for diabetes and partial 
lipodystrophy in three generations. Physical examination 
revealed abdominal obesity (waist-circumference 86 cm, 
BMI 27 kg/m2), android/cushingoidal habitus, acanthosis 
nigricans in axillae and neck, hirsutism, enlarged liver, and 
pseudohypertrophy of muscles of limbs with partial 
lipodystrophy. Based on oral glucose tolerance test diabetes 
was diagnosed (HOMA-IR 14). HbA1c was 9.2% (78 
mmol/mol). Diabetes autoantibodies were negative. Lab tests 
revealed also dyslipidemia (total cholesterol 6.42 mmol/l, 
triglicerydes 7.42 mmol/l, HDL cholesterol 0.73 mmol/l) and 
elevated liver enzymes. Ultrasonography revealed  steatosis 
hepatis and polycystic ovaries. Genetic tests confirmed 
that she is a carrier of heterozygous missense mutation 
(c.1444C>T; R482W) in the LMNA gene. Lifestyle 
changes, metformin dosage 500 mg three times a day and 
ursodeoxycholic acid were introduced as her therapy. After 
4 months of this treatment HbA1c levels dropped 5.8% (40 
mmol/mol). Moreover an improvement of lipid profile, 
liver tests and 2 kg body weight loss were observed.  
Diabetes mellitus as a component of MS in a young obese 
patient should be diagnosed individually. When other non-
typical for diabetes mellitus clinical signs and symptoms 
exist with positive, multigenerational family history, 
genetic causes of MS should be taken into consideration. 
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Introduction 
Metabolic Syndrome (MS) is a cluster of conditions - increased 
blood pressure, a high blood sugar level, excess body fat around 
the waist and abnormal cholesterol levels - that occur together, 
increasing the risk of the heart disease, stroke and diabetes with 
all its complications [1]. Moreover metabolic syndrome is also 
associated with an increased risk of some common cancers [2, 
3]. 
The underlying pathophysiology of metabolic syndrome seems 
to be related to insulin resistance [4]. The exact causes of 
insulin resistance are not completely understood. Insulin 
resistance is caused by a persistently high level of insulin over a 
prolonged period of time that eventually causes the body's 
sensitivity to insulin to decrease. The major contributors to 
insulin resistance seem to be excess weight and physical 
inactivity, so risk factors associated with lifestyle, which could 
be modified. However some cases of insulin resistance are 
associated with not modifiable genetic risk factors. MS is 
common in adults but it is also observed in obese children. 
Metabolic syndrome can also occur in lean individuals, 
suggesting that obesity is a marker for the syndrome, not a 
cause [5].  
The definition of MS is a matter of debate since 1998 [6]. In 
2009 the International Diabetes Federation (IDF) and American 
Heart Association (AHA) defined MS as three (or more) of the 
following factors: increased waist circumference, raised 
triglycerides, reduced HDL-cholesterol, raised blood pressure, 
and raised fasting plasma glucose. In 2007 IDF proposed a 
definition of MS for children 10-y-old or older [7]. For 
teenagers older than 16 yrs existing IDF criteria of MS for 
adults should be used. Some clinical observations suggest that 
in very young person the genetic cause of MS should be 
searched and identified.  
There is an ongoing discussion on the diagnosis clinical 
usefulness of MS. 
Although the metabolic syndrome appears to have limited utility 
for  the identification of individuals at increased risk of type 2 
diabetes mellitus or cardio-vascular diseases, the diagnosis of 
the metabolic syndrome presents an opportunity to rationalize 
health services to deliver coordinated care to those with MS [8, 
9]. 
The aim of the study is to present a teenager with metabolic 
syndrome due to LMNA mutation existing also in other 
members of the patient’s family. 
Case Report 
A 17.6-yr-old, Caucasian overweight girl (BMI 27 
kg/m2) of non-consanguineous couple of Central-European 
descent, with hirsutism/androgenisation and olighomenorrhea 
was admitted to our department with a suspicion of diabetes 
mellitus due to incidental, causal blood glucose 393 mg/dl (21.8 
mmol/l). She did not present with typical Diabetes Mellitus 
(DM) signs and symptoms. Her family history was positive for 
DM (grand-mother, father’s brother), disorders of carbohydrate 
metabolism (impaired fasting glucose – father, glucose 
intolerance - older sister) and PolyCystic OvarieS, PCOS (older 
sister). Her medical revealed increased appetite, excessive 
weight gain, appearance of acanthosis nigricans, hirsutism, 
androgenoidal habitus, irregular menses observed since 13 yrs 
of life. Puberty appeared normal, menarche occurred at the age 
12.3 yrs. At the age of 15 yrs she was diagnosed with 
depression and pharmacological treatment had been 
administrated over one year with good result.  
 Being admitted to the hospital she presented with a good 
clinical condition. The overweight (50% excess of body weight 
for her height) with abdominal obesity (WHR 0.9) [Figure 1], 
android habitus with cushingoidal face, severe acanthosis 
nigricans in neck and axillae regions, acnae on face and upper 
trunk, and hirsutism (10 pts in Ferriman-Galleway score) were 
observed. In addition pseudohypertrophy of muscles of limbs 
with partial lipodystrophy (extremitas and gluteal region) 
[Figure 2] and enlargement of liver were notice. Blood pressure 
was normal. Some of her family members, whose with 
carbohydrate metabolism disorders presented with similar 
phenotype [Figure 3]. 
DM was diagnosed on the basis of an oral glucose tolerance 
test. Fasting plasma glucose was 162 mg/dl (9 mmol/l) and 2-
hour plasma glucose 252 mg/dl (14 mmol/l). Insulin levels were 
35.8 IU/ml and 88.5 IU/ml, respectively. High fasting level of
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Figure 1 
Growth, Body mass and BMI charts of the patient with LMNA mutation. 
Figure: 2 
Lipoatrophy of legs and muscular hypertrophy in calves of the 
patients with LMNA mutation. 
Figure: 3 
The family pedigree of the patient with LMNA mutation. 
■ confirmed diagnosis ■ suspected diagnosis
insulin and high HOMA index - 14 indicated severe insulin 
resistance. High HbA1c 9.2% (78 mmol/mol) confirmed the 
diagnosis of DM. Further diagnostics revealed also dyslipidemia 
with elevated total cholesterol (6.42 mmol/l), triglycerides (7.42 
mmol/l), and LDL cholesterol (3.34 mmol/l) and decreased 
HDL cholesterol (0.73 mmol/l). Moreover elevated liver 
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enzymes such as AST 161.5 U/L (N 15-45), ALT 166.6 U/L (N 
10-40), and GGT 39 U/L (N 10-29) were observed. Diabetes 
autoantibodies were negative: Islet cell antibodies - ICA 0 
(N<0), Glutamic Acid Decarboxylase antibodies - anti-GAD 1 
IU/ml (N<10). 
In the differential diagnosis of elevated liver enzymes hepatic 
viral infections (HBs antigen – negative, anti-HCV antibodies – 
negative) were excluded. Detailed assessment of the liver 
function showed normal results of albumin level - 45.5 g/l (N 
37-56), protrombin (prothrombin  index – 99.8 %, INR (Quick 
index) - 1.0) ammonia - 24.5 μmol/l (N 20-70), total bilirubin 
20.9 - µmol/l (N 3-22) and alkaline phosphatase - 51 U/l (N 58-
237). Ultrasonography of liver revealed hyperechoic liver and 
blurring of vascular margins characteristic for staetosis hepatis, 
so Non-Alcoholic Fat Liver Disease, NAFLD was diagnosed.  
In the diagnostic process of oligomennorrea, LH - 2.93 mIU/ml 
(N 1-21.55), FSH - 4.16 mIU/ml (N 1.5-8.77),  estrogen - 116.2 
pg/ml (N 14 – 238) and testosterone 0.48 ng/ml (N 0.1-1.12) 
levels were assessed and were within normal ranges for a 
second phase of menstrual cycle. Thyroid function: TSH 5.39 
ulU/ml, FT4 17.1 pmol/l  (N 10-25),  aTPO <5.5 IU/ml (N 0-60) 
was assessed and revealed subclinical hypothyroidism. In the 
assessment of adrenal function an ACTH level - 30.6  pg/ml (N 
10-60) and a cortisol profile: 8.00 AM 219.6 ng/ml (N 50-230) 
and 8.00 PM  55.5 ng.ml were checked and were normal so test 
with dexametason was not made. Moreover the level of 17-OHP 
was measured and was normal - 1.43 ng/ml (N 1-5.2). The only 
abnormalities were slightly elevated level of DHEA-S - 288 
ug/dl (N 20-260) and notably decreased the level of SHBG 5.9 
nmol/ml (N 21-139). Ultrasonograhy of pelvis revealed 
presence of an ovarian cyst/cysts (size 40x40x38 mm) at left. 
Tumor markers were checked: AFP 2.7 ng/ml (N 0-10), β-HCG 
4.9 mIU/ml (N 0-5), and Ca 125 25.71 U/ml (N 0-35) and were 
negative. 
 On the base of above-mentioned data, she was diagnosed with 
MS and polycystic ovarian syndrome, PCOS. Despite the 
introduction of the initial treatment such as diet and physical 
activity, her 24 hour blood glucose profile was still abnormal. 
Therefore,  metformin was introduced. After three days of 
treatment with metformin ALT level increased - 183.4 U/L (N 
10-40), therefore metformin was replaced with insulin therapy - 
Insulin analog (glulisin) for main meals. After three weeks of 
this treatment a decrease of the ALT level - 83 U/l was 
observed, so again metformin was replaced with insulin therapy.  
Follow-up after four months of treatment with metformin 
dosage 500 mg three times a day, the reduction of body weight -
2.4 kg (body weight 70 kg), normalization of menstrual cycles 
and the level of HbA1c - 5.8% (40 mmol/mol). Moreover 
improvement of lipids profile: total cholesterol 4.68 mmol/l, 
triglicerides 3.51 mmol/l, HDL cholesterol 0.86 mmol/l, LDL 
cholesterol  3.11 mmol/l was observed. Also improvement of 
liver tests: ALT 66 U/L and AST 40.6 U/L was visible. 
Due to observed abnormalities and similar phenotypes 
in the family of our patient genetic cause of insulin resistance in 
the patient such as: MS, NAFLD, severe acanthosis nigricans, 
PCOS was suspected. According WHO classification, diabetes 
mellitus type 3b consisting of different types of diabetes due to 
genetic causes of insulin resistance. Among them the most 
probable for the patient had been seemed to be type 2 of 
familiar partial lipodystrophy, FDLP2 caused by the mutation in 
lamin gene, LMNA. Therefore DNA of the patient was 
extracted and sent to the reference genetic laboratory in Lodz, 
Poland. Genetic analysis using Sanger DNA sequencing 
revealed that the patient was a carrier of heterozygous missense 
mutation (c.1444C>T; R482W) in the LMNA gene (OMIM 
151660). LMNA mutation was also found in some members of 
her family [Figure 3]. The diagnosis of the Familial Partial 
Lipodystrophy type 2, named the Dunnigan type FPLD was 
made. 
Discussion 
Familial Partial Lipodystrophy type 2, named the 
Dunnigan type FPLD is a rare, about 1: 10 mln, form of 
monogenic form of insulin resistance [10-12]. It is caused by the 
mutation of LMNA gene [13, 14]. Lamin is a filamentous 
structure located between the inner membrane of the nuclear 
envelope and the chromatin in the nucleus. Nuclear lamins are 
responsible for: shape and architecture of the nucleus, nuclear 
envelope assembly, organization and anchoring of chromatin, 
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and the nuclear channel system. Therefore lamins are essential 
for DNA replication and mRNA transcription [15]. Because of 
such multiple role s of the lamina in cells, mutations in the 
LMNA gene result in the diverse group of disorders (muscular 
dystrophies, lipodystrophies, neuropaties, systemic 
laminopathies) [16, 17]. Because lamin  participates in the 
insulin transduction pathway, LMNA mutation could cause 
insulin resistance, the clinical picture of FPLD2. 
The essential hallmark of the FPLD2 is abnormal distribution of 
subcutaneous fat [10]. Partial lipodystrophy with lipoatrophy of 
limbs, gluteal region and trunk coexist with cervico-facial 
accumulation. The presence of excess adipose tissue in the face 
and neck giving the pseudo-Cushingoid appearance. Patients 
with FDLP are born with normal fat distribution. Alteration in 
body fat distribution starts gradually at the time of puberty. 
Furthermore PDLP patients have normal stores of 
intermuscular, intra-abdominal, intrathoracic and bone marrow 
fat. In spite of abnormal fat distribution muscular hypertrophy is 
observed, predominant in calves [14]. Other clinical features of 
the syndrome are associated with insulin resistance, such as: 
acathosis nigricans, obesity, pre-diabetes or diabetes; 
hyperandrogenism, hirsutism, irregular menses and policystic 
ovaries, hepatic steatosis, hepatomegaly; lipid abnormalities: 
high levels of serum total cholesterol and TG and low levels of 
HDL cholesterol hypertriglyceridemia. All of the above 
mentioned abnormalities were present in the probant. Women 
are more severely affected with metabolic complications. This 
fact was confirmed in the described patients family. Genetic 
confirmation of FDLP explain the lack of an effect of life style 
management initially indicated in patients with MS without 
genetic abnormalities [18]. Moreover the result of genetic tests 
allows to take into consideration replacement of metformin 
treatment with thiazolinediones, eventually leptin  [19, 20, 21]. 
In FDLP patients glitazones may be initially effective however 
their side effects should be taken into consideration. Glitazones 
can cause further accumulation of fat in the face and neck [22]. 
In partial lipodystrophy, leptin replacement has limited value 
with improvement of hypertriglyceridemia but not 
hyperglycemia [23]. 
The patients with FDLP should be monitored due to different 
metabolic complications of the disease throughout all her life. 
Because of known clinical risk of cardiovascular complications 
in patients with MS appropriate prophylaxis and treatment 
should be used. The younger patient with MS the longer time of 
exposition on metabolic risk factors. There is still limited 
number of reports of the syndrome and it is regarded as 
underrecognized [24]. The LMNA R482 mutation has an 
extremely strong statistical association with FDLP [14]. Carriers 
of the LMNA R482W mutation were recognized under the 
circumstances of diabetes treatment [25] Particularly this 
LMNA R482W mutation FPLD induces clinical early 
atherosclerosis and in vitro endothelial dysfunction [26]. 
Carriers of the LMNA R482W mutation present with 
dyslipidemia as an early and prominent feature [27]. Particularly 
dyslipidemia but also other components of MS increase blood 
viscosity. Chronic blood viscosity seems to play an important 
role in the pathogenesis of vascular diseases [28].  
In PDLP also psychologic/psychiatric management is often 
necessary as it is impossible to change the abnormal appearance 
with pharmacological treatment. Due to variety of clinical 
picture of LMNA mutation genetic counseling should continued 
in FDLP families.  
In conclusion, FPLD should be taken into consideration in 
young people with MS coexisting with other disorders 
associated with insulin resistance, abnormal distribution of 
subcutaneous fat and with family history of similar 
abnormalities.  
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